In prostate cancers, CAF-derived neuregulin 1 NRG1 promotes resistance in tumor cells by activating HER3 involving the NRG1/HER3 axis, proving a paracrine mechanism of antiandrogen resistance in a paracrine manner, as presented above [64]. This evidence concerns the gene ERBB3 and prostate carcinoma.